Gyre Therapeutics (NASDAQ:GYRE) COO Weiguo Ye Sells 9,400 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE) COO Weiguo Ye sold 9,400 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $6.15, for a total transaction of $57,810.00. Following the completion of the sale, the chief operating officer directly owned 700,000 shares in the company, valued at approximately $4,305,000. This represents a 1.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Weiguo Ye also recently made the following trade(s):

• On Thursday, May 21st, Weiguo Ye sold 12,820 shares of Gyre Therapeutics stock. The stock was sold at an average price of $6.15, for a total transaction of $78,843.00.

Gyre Therapeutics Stock Down 1.9%

Shares of GYRE stock opened at $6.06 on Friday. The company’s fifty day simple moving average is $7.24 and its 200-day simple moving average is $7.60. The firm has a market cap of $587.99 million, a PE ratio of -67.33 and a beta of 2.03. Gyre Therapeutics, Inc. has a 12 month low of $5.97 and a 12 month high of $11.61.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The business had revenue of $37.20 million during the quarter, compared to the consensus estimate of $36.30 million. Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%. On average, equities analysts predict that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on GYRE. Wall Street Zen lowered shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings lowered shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, Zacks Research lowered shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $17.00.

Institutional Trading of Gyre Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alliancebernstein L.P. raised its position in Gyre Therapeutics by 9.5% during the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after acquiring an additional 1,900 shares in the last quarter. Barclays PLC raised its position in Gyre Therapeutics by 38.3% during the fourth quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after acquiring an additional 5,135 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Gyre Therapeutics during the third quarter worth $111,000. Wells Fargo & Company MN raised its position in Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after acquiring an additional 7,361 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares during the period. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.